Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Malkin

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Neuro-Oncology|September 7, 2021
Working memory training for adult glioma patients: a proof-of-concept studySarah Ellen Braun, Farah J Aslanzadeh, Autumn Lanoye, et al.
Neuro-Oncology|January 17, 2014
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade gliomaKathleen M Schmainda, Melissa Prah, Jennifer Connelly, et al.
Journal of Neuro-Oncology|August 28, 2010
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomasBenjamin M Ellingson, Mark G Malkin, Scott D Rand, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 8, 2013
Effects of perfusion on diffusion changes in human brain tumorsAlexander D Cohen, Peter S LaViolette, Melissa Prah, et al.
Neuro-Oncology|February 6, 2013
Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade gliomaPeter S LaViolette, Alex D Cohen, Melissa A Prah, et al.
Journal of Neuro-Oncology|December 14, 2005
Systemic high-dose intravenous methotrexate for central nervous system metastasesAndrew B Lassman, Lauren E Abrey, Gaurav D Shah, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 27, 2010
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularityBenjamin M Ellingson, Mark G Malkin, Scott D Rand, et al.
Magnetic Resonance in Medicine|March 18, 2011
Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRIBenjamin M Ellingson, Peter S LaViolette, Scott D Rand, et al.
Neuro-Oncology|July 26, 2014
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade gliomaPeter S LaViolette, Nikolai J Mickevicius, Elizabeth J Cochran, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade GliomaAndrew S Poklepovic, Palak Shah, Mary Beth Tombes, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Neuro-Oncology|September 7, 2021
Working memory training for adult glioma patients: a proof-of-concept studySarah Ellen Braun, Farah J Aslanzadeh, Autumn Lanoye, et al.
Neuro-Oncology|January 17, 2014
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade gliomaKathleen M Schmainda, Melissa Prah, Jennifer Connelly, et al.
Journal of Neuro-Oncology|August 28, 2010
Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomasBenjamin M Ellingson, Mark G Malkin, Scott D Rand, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 8, 2013
Effects of perfusion on diffusion changes in human brain tumorsAlexander D Cohen, Peter S LaViolette, Melissa Prah, et al.
Neuro-Oncology|February 6, 2013
Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade gliomaPeter S LaViolette, Alex D Cohen, Melissa A Prah, et al.
Journal of Neuro-Oncology|December 14, 2005
Systemic high-dose intravenous methotrexate for central nervous system metastasesAndrew B Lassman, Lauren E Abrey, Gaurav D Shah, et al.
Journal of Magnetic Resonance Imaging : JMRI|February 27, 2010
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularityBenjamin M Ellingson, Mark G Malkin, Scott D Rand, et al.
Magnetic Resonance in Medicine|March 18, 2011
Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRIBenjamin M Ellingson, Peter S LaViolette, Scott D Rand, et al.
Neuro-Oncology|July 26, 2014
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade gliomaPeter S LaViolette, Nikolai J Mickevicius, Elizabeth J Cochran, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade GliomaAndrew S Poklepovic, Palak Shah, Mary Beth Tombes, et al.
Pageof 3